Jump to content

Catalent: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Undid revision 912149777 by 69.225.54.7 (talk) rmv press release copy; see https://www.prweb.com/releases/2015/04/prweb12653322.htm
Cleovulcan (talk | contribs)
206 edits
cleaning up copy
Line 36: Line 36:


===Formation of Catalent in 2007===
===Formation of Catalent in 2007===
In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.<ref name=BLKSTN>{{cite news|title=Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group|url=http://www.blackstone.com/news-views/press-releases/details/cardinal-health-completes-sale-of-pharmaceutical-technologies-and-services-segment-to-the-blackstone-group|publisher=Blackstone Group|date=10 April 2007|location=Dublin, Ohio}}</ref>
In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as ''Catalent Pharma Solutions''.<ref name=BLKSTN>{{cite news|title=Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group|url=http://www.blackstone.com/news-views/press-releases/details/cardinal-health-completes-sale-of-pharmaceutical-technologies-and-services-segment-to-the-blackstone-group|publisher=Blackstone Group|date=10 April 2007|location=Dublin, Ohio}}</ref>


===After 2007 and initial public offering===
===After 2007 and initial public offering===
In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore.<ref name=APTUIT>{{cite news|title=Catalent completes Aptuit deal|url=http://www.biopharma-reporter.com/Bio-Developments/Catalent-completes-Aptuit-deal|accessdate=7 April 2015|publisher=BioPharma-reporter.com|date=20 February 2012}}</ref> Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.<ref name=MC /><ref>{{Cite web|url=https://www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html|title=2 big companies and 1 small one to target in the pharma/biotech space|last=Wasserman|first=Robert|date=2016-09-08|website=TheStreet|language=en|access-date=2019-07-09}}</ref><ref>{{Cite web|url=https://fif.cnsmedia.com/a/eNnejRzm4IA=|title=Gelita and R.P. Scherer End 60 Year Joint Venture|website=.foodingredientsfirst.com/|access-date=2019-07-09}}</ref>
In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the United States, two sites in the [[United Kingdom]] and one in [[Singapore]].<ref name=APTUIT>{{cite news|title=Catalent completes Aptuit deal|url=http://www.biopharma-reporter.com/Bio-Developments/Catalent-completes-Aptuit-deal|accessdate=7 April 2015|publisher=BioPharma-reporter.com|date=20 February 2012}}</ref> Catalent also acquired all remaining shares for the R.P Scherer site in [[Eberbach (Baden)|Eberbach, Germany]].<ref name=MC /><ref>{{Cite web|url=https://www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html|title=2 big companies and 1 small one to target in the pharma/biotech space|last=Wasserman|first=Robert|date=2016-09-08|website=TheStreet|language=en|access-date=2019-07-09}}</ref><ref>{{Cite web|url=https://fif.cnsmedia.com/a/eNnejRzm4IA=|title=Gelita and R.P. Scherer End 60 Year Joint Venture|website=.foodingredientsfirst.com/|access-date=2019-07-09}}</ref>


In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil.<ref name="BRAZIL">{{cite news|last1=Stanton|first1=Dan|title=Catalent's Brazilian acquisition supports global softgel strategy|url=http://www.in-pharmatechnologist.com/Drug-Delivery/Catalent-s-Brazilian-acquisition-supports-global-softgel-strategy|accessdate=7 April 2015|publisher=inPharma-technologist.com|date=10 October 2013}}</ref>
In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a [[China]]-based company, and Relthy Laboratories in [[Brazil]].<ref name="BRAZIL">{{cite news|last1=Stanton|first1=Dan|title=Catalent's Brazilian acquisition supports global softgel strategy|url=http://www.in-pharmatechnologist.com/Drug-Delivery/Catalent-s-Brazilian-acquisition-supports-global-softgel-strategy|accessdate=7 April 2015|publisher=inPharma-technologist.com|date=10 October 2013}}</ref>


Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).<ref name=IPO>{{cite news|title=Catalent Issues Initial Public Offering|url=http://www.pharmtech.com/catalent-issues-initial-public-offering|accessdate=7 April 2015|agency=Pharmaceutical Technology Sourcing and Management|issue=8|publisher=PharmTech.com|date=4 August 2014}}</ref> The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014.<ref name=IPO />
Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).<ref name=IPO>{{cite news|title=Catalent Issues Initial Public Offering|url=http://www.pharmtech.com/catalent-issues-initial-public-offering|accessdate=7 April 2015|agency=Pharmaceutical Technology Sourcing and Management|issue=8|publisher=PharmTech.com|date=4 August 2014}}</ref>
The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014.<ref name="IPO" />


In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.<ref name=":0" /><ref>{{Cite web|url=https://www.crunchbase.com/acquisition/catalent-pharma-solutions-acquires-micron-technologies--56b4967e|title=Catalent Pharma Solutions acquires Micron Technologies - 2014-11-13|website=Crunchbase|language=en|access-date=2019-06-25}}</ref> The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.<ref name=":0">{{Cite web|url=http://www.pharmtech.com/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio|title=Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio|last=|first=|date=|website=Pharmtech|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133M deal.<ref>{{Cite web|url=https://www.fiercepharma.com/manufacturing/catalent-extends-expansion-130m-deal-for-juniper-pharmaceuticals|title=Catalent extends expansion with $133M deal for Juniper Pharmaceuticals|website=FiercePharma|language=en|access-date=2019-08-16}}</ref>
In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.<ref name=":0" /><ref>{{Cite web|url=https://www.crunchbase.com/acquisition/catalent-pharma-solutions-acquires-micron-technologies--56b4967e|title=Catalent Pharma Solutions acquires Micron Technologies - 2014-11-13|website=Crunchbase|language=en|access-date=2019-06-25}}</ref> The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.<ref name=":0">{{Cite web|url=http://www.pharmtech.com/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio|title=Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio|last=|first=|date=|website=Pharmtech|archive-url=|archive-date=|dead-url=|access-date=}}</ref> In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133M deal.<ref>{{Cite web|url=https://www.fiercepharma.com/manufacturing/catalent-extends-expansion-130m-deal-for-juniper-pharmaceuticals|title=Catalent extends expansion with $133M deal for Juniper Pharmaceuticals|website=FiercePharma|language=en|access-date=2019-08-16}}</ref>
Line 49: Line 51:
Alessandro Maselli was appointed as President and Chief Operating Officer in 2019, a newly created position within Catalent.<ref>{{Cite web|url=https://finance.yahoo.com/news/catalent-names-alessandro-maselli-president-120000487.html|title=Catalent Names Alessandro Maselli President and Chief Operating Officer|website=finance.yahoo.com|language=en-US|access-date=2019-02-19}}</ref>
Alessandro Maselli was appointed as President and Chief Operating Officer in 2019, a newly created position within Catalent.<ref>{{Cite web|url=https://finance.yahoo.com/news/catalent-names-alessandro-maselli-president-120000487.html|title=Catalent Names Alessandro Maselli President and Chief Operating Officer|website=finance.yahoo.com|language=en-US|access-date=2019-02-19}}</ref>


In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new [[Zydis]] lines, changes to one of their facilities in Swindon, UK, and a custom suite for commercial equipment.<ref>{{Cite web|url=http://www.pharmtech.com/catalent-invests-zydis-ultra-commercialization|title=Catalent Invests in Zydis Ultra Commercialization|last=|first=|date=|website=pharmtech.com|archive-url=|archive-date=|dead-url=|access-date=}}</ref>
In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new [[Zydis]] lines, changes to one of their facilities in [[Swindon (UK Parliament constituency)|Swindon, UK,]] and a custom suite for commercial equipment.<ref>{{Cite web|url=http://www.pharmtech.com/catalent-invests-zydis-ultra-commercialization|title=Catalent Invests in Zydis Ultra Commercialization|last=|first=|date=|website=pharmtech.com|archive-url=|archive-date=|dead-url=|access-date=}}</ref>


== Financials ==
== Financials ==

Revision as of 13:44, 29 August 2019

Catalent, Inc.
Company typePublic company
NYSE: CTLT
S&P 400 Component
IndustryPharmaceuticals
PredecessorCardinal Health PTS
Founded2007
HeadquartersSomerset, New Jersey, US
Number of locations
34
Key people
John Chiminski
(President, CEO),
Joseph Wetteny
(Executive Vice President, CFO)
ServicesDrug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
RevenueUS$2,463.4 million (2018)[1]
US $271.1 million (2018)[1]
US $83.6 million (2018)[2]
Number of employees
11,000 (2019)[3]
Websitewww.catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a Somerset, New Jersey pharmaceutical company.

On July 31, 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).

History

Before 2007

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[4] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[5]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[6] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[7]

In 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[4] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[7]

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[4]

In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[4] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[4]

In 2004-2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple other acquisitions.[4]

Formation of Catalent in 2007

In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[8]

After 2007 and initial public offering

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore.[9] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[6][10][11]

In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil.[12]

Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[13]

The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014.[13]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[14][15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[14] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133M deal.[16]

Alessandro Maselli was appointed as President and Chief Operating Officer in 2019, a newly created position within Catalent.[17]

In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines, changes to one of their facilities in Swindon, UK, and a custom suite for commercial equipment.[18]

Financials

Annual Financial Table[19]
# 2016 2017 2018
Sales/Revenue 1.85B 2.08B 2.46B
Total Current Assets 790.2M 1.06B 1.24B
Net Operating Cash Flow 155.3M 299.5M 374.5M

References

  1. ^ a b "Catalent, Inc. 2018 Annual Report". Catalent Investors. Retrieved 25 January 2019.
  2. ^ "The Thing About Catalent, Inc. (CTLT) Growth".
  3. ^ "Financial News". Investor. Retrieved 6 February 2019.
  4. ^ a b c d e f "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015. {{cite web}}: Unknown parameter |deadurl= ignored (|url-status= suggested) (help)
  5. ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  6. ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  7. ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  8. ^ "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  9. ^ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
  10. ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
  11. ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
  12. ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
  13. ^ a b "Catalent Issues Initial Public Offering". No. 8. PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  14. ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  15. ^ "Catalent Pharma Solutions acquires Micron Technologies - 2014-11-13". Crunchbase. Retrieved 25 June 2019.
  16. ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". FiercePharma. Retrieved 16 August 2019.
  17. ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
  18. ^ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com. {{cite web}}: Cite has empty unknown parameter: |dead-url= (help)
  19. ^ "Catalent Inc". www.marketwatch.com. Retrieved 11 February 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Catalent&oldid=913038051"